Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep

C.C.P. Celma, M. Boyce, P.A. van Rijn, M. Eschbaumer, K. Wernike, B. Hoffmann, M. Beer, K. De Clercq, P. Roy

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)

Abstract

Since 1998, nine of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe and serotype 8 has suddenly emerged in northern Europe causing considerable economic losses, both direct (mortality and morbidity) but also indirect due to restriction in animal movements. Therefore many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV-1 serotype (disabled infectious single cycle, DISC) to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail as multivalent vaccine candidate. All vaccinated animals were seroconverted and developed a neutralizing antibody response against their respective serotype. After challenge with the virulent strains at 21 days post vaccination vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference in protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.
Original languageEnglish
Pages (from-to)9856-9864
JournalJournal of Virology
Volume87
Issue number17
DOIs
Publication statusPublished - 2013

Fingerprint

Bluetongue virus
Sheep
serotypes
Vaccines
vaccines
Viruses
sheep
viruses
cattle
Reverse Genetics
animals
Subunit Vaccines
subunit vaccines
Viremia
viremia
Northern European region
Neutralizing Antibodies
crossover interference
neutralizing antibodies
Antibody Formation

Keywords

  • time rt-pcr
  • synthetic rna
  • particles
  • europe
  • vaccination
  • serotype-8
  • strains
  • epidemic
  • proteins
  • efficacy

Cite this

Celma, C.C.P. ; Boyce, M. ; van Rijn, P.A. ; Eschbaumer, M. ; Wernike, K. ; Hoffmann, B. ; Beer, M. ; De Clercq, K. ; Roy, P. / Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. In: Journal of Virology. 2013 ; Vol. 87, No. 17. pp. 9856-9864.
@article{7400cea1995a4ffe985b1636acfbd563,
title = "Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep",
abstract = "Since 1998, nine of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe and serotype 8 has suddenly emerged in northern Europe causing considerable economic losses, both direct (mortality and morbidity) but also indirect due to restriction in animal movements. Therefore many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV-1 serotype (disabled infectious single cycle, DISC) to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail as multivalent vaccine candidate. All vaccinated animals were seroconverted and developed a neutralizing antibody response against their respective serotype. After challenge with the virulent strains at 21 days post vaccination vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference in protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.",
keywords = "time rt-pcr, synthetic rna, particles, europe, vaccination, serotype-8, strains, epidemic, proteins, efficacy",
author = "C.C.P. Celma and M. Boyce and {van Rijn}, P.A. and M. Eschbaumer and K. Wernike and B. Hoffmann and M. Beer and {De Clercq}, K. and P. Roy",
year = "2013",
doi = "10.1128/JVI.01514-13",
language = "English",
volume = "87",
pages = "9856--9864",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "17",

}

Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. / Celma, C.C.P.; Boyce, M.; van Rijn, P.A.; Eschbaumer, M.; Wernike, K.; Hoffmann, B.; Beer, M.; De Clercq, K.; Roy, P.

In: Journal of Virology, Vol. 87, No. 17, 2013, p. 9856-9864.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep

AU - Celma, C.C.P.

AU - Boyce, M.

AU - van Rijn, P.A.

AU - Eschbaumer, M.

AU - Wernike, K.

AU - Hoffmann, B.

AU - Beer, M.

AU - De Clercq, K.

AU - Roy, P.

PY - 2013

Y1 - 2013

N2 - Since 1998, nine of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe and serotype 8 has suddenly emerged in northern Europe causing considerable economic losses, both direct (mortality and morbidity) but also indirect due to restriction in animal movements. Therefore many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV-1 serotype (disabled infectious single cycle, DISC) to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail as multivalent vaccine candidate. All vaccinated animals were seroconverted and developed a neutralizing antibody response against their respective serotype. After challenge with the virulent strains at 21 days post vaccination vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference in protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.

AB - Since 1998, nine of the 26 serotypes of bluetongue virus (BTV) have spread throughout Europe and serotype 8 has suddenly emerged in northern Europe causing considerable economic losses, both direct (mortality and morbidity) but also indirect due to restriction in animal movements. Therefore many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for a broad range of BTV serotypes are currently being developed by different laboratories. Here we exploited a reverse genetics-based replication-deficient BTV-1 serotype (disabled infectious single cycle, DISC) to generate a series of DISC vaccine strains. Cattle and sheep were vaccinated with these viruses either singly or in cocktail as multivalent vaccine candidate. All vaccinated animals were seroconverted and developed a neutralizing antibody response against their respective serotype. After challenge with the virulent strains at 21 days post vaccination vaccinated animals showed neither any clinical reaction nor viremia. Further, there was no interference in protection with a multivalent preparation of six distinct DISC viruses. These data indicate that a very rapid response vaccine could be developed based on which serotypes are circulating in the population at the time of an outbreak.

KW - time rt-pcr

KW - synthetic rna

KW - particles

KW - europe

KW - vaccination

KW - serotype-8

KW - strains

KW - epidemic

KW - proteins

KW - efficacy

U2 - 10.1128/JVI.01514-13

DO - 10.1128/JVI.01514-13

M3 - Article

VL - 87

SP - 9856

EP - 9864

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 17

ER -